The combination of darovasertib (IDE196) and crizotinib (Xalkori) demonstrated clinical activity and an acceptable safety profile when utilized in first- and any-line patients with metastatic uveal melanoma, according to interim results from a phase 2 trial (NCT03947385).
Clinical Trials
Updated Results From KEYNOTE-695 Do Not Meet ORR Primary Endpoint in Advanced Melanoma
Primary results from the phase 2 KEYNOTE-695 study (NCT03132675) did not meet the prespecified end point of overall response rate (ORR) for previously treated patients with unresectable or metastatic (Stage III/IV) melanoma to the combination of pembrolizumab (Keytruda) and a proprietary interleukin 12 (IL–12) intratumoral tavokinogene telseplasmid and electroporation (TAVO-EP).
Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma
CAMBRIDGE, England–(BUSINESS WIRE)–Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA).
Adding New Vaccine Type to Leading Immunotherapy Dramatically Reduced Melanoma Recurrence
The combination of an experimental mRNA vaccine with an immunotherapy reduced the likelihood of melanoma recurring or causing death by 44 percent when compared to immunotherapy alone, a new clinical trial shows.